Royalty Report: Drugs, Therapeutic, Disease – Collection: 8916

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • Vaccine
  • Delivery
  • Cancer
  • Biotechnology
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 8916

License Grant
A pharma company purchased another pharma from its parent company.
License Property
The main technologies being acquired are a proprietary vaccine delivery platform (Virosome), as well as intranasal influenza and respiratory synctial virus (RSV) vaccines and Herpes Simplex virus (HSV) vaccine development.
Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 4244

License Grant
The Licensor entered into a License Agreement with the Korean Licensee, to develop, manufacture and commercialize influenza vaccines using the Licensee's proprietary VLP technology.
License Property
The Licensor is a clinical-stage biopharmaceutical company focused on developing novel and effective recombinant vaccines. These vaccines leverage the Licensor's platform technology coupled with a single-use bioprocessing production system to develop virus-like particle (VLP) vaccines, as well as recombinant nanoparticle vaccines.

VLPs are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Company’s VLPs resemble the virus they were engineered to mimic, but lack the genetic material to replicate the virus and its single-use bioprocessing production technology uses insect cells rather than chicken eggs or mammalian cells.

The Licensor’s current product targets include VLP vaccines against seasonal and pandemic (including H5N1) influenza and a recombinant nanoparticle vaccine against Respiratory Syncytial Virus (RSV).

The upfront payment has been deferred and will be recognized as revenue when certain obligations in the agreement are satisfied.

Field of Use
At its own cost, the Licensee is responsible for funding its clinical development of the influenza VLP vaccines and completing a manufacturing facility in South Korea.

IPSCIO Record ID: 27993

License Grant
The Company hereby grants the exclusive right and license in, to, and under the Novavax IP in the Field within the Territory.  The exclusive license shall be for the period in which any Novavax IP or patents covering the Joint Improvement(s) shall remain valid and enforceable, unless earlier terminated as provided.
License Property
The Licensor has certain proprietary know-how in the field of encapsulated drug delivery systems and has developed certain proprietary adjuvants, such as a Novasome® delivery system; and the Licensee has certain proprietary know-how in the field of vaccines and has developed and continues to develop proprietary vaccines, especially a vaccine comprising antigenic determinants of an influenza virus.

The parties desire for Licensee to develop, manufacture, market, distribute and sell a product for treating or preventing influenza virus and/or infection, such as a vaccine comprising antigenic determinants of an influenza virus, like Fluogen®, which includes a proprietary adjuvant developed by Licensor.

Field of Use
Field shall mean (a) the use of Novavax IP in any manner whatsoever to develop, create, invent, manufacture, promote, market, offer-for-sale, sell, import and/or export an Influenza Product involved in or concerned with the treatment or prevention of influenza virus or any other purpose for which an Influenza Product may be indicated, and (b) the subsequent exploitation of an Influenza Product in the territory.

IPSCIO Record ID: 243429

License Grant
This agreement is for the use of Herpes Simplex Virus Type 2 Antigens as Immunoprophylaxis or Immunotherapy to prevent or treat HSV Infections in Humans.

The University grants a Co-Exclusive license and a Tri-Exclusive license under the Licensed Patents to manufacture, have manufactured on Companys behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Field of Use in the Territory.

Tri-Exclusive means, with respect to a license, that such license may only be granted to Company and two Third Parties.

License Property
The research relates to the use of Herpes Simplex Virus Type 2 (HSV2) antigens as immunoprophylaxis or immunotherapy to prevent or treat HSV infections in humans.

Genital herpes is a sexually transmitted disease caused by the herpes simplex viruses HSV-1 or HSV-2, and in extreme cases, can appear in and about the eyes, esophagus, trachea, brain, and arms and legs.

Field of Use
The Field of Use means therapy that is administered to prevent or treat HSV2 infection.

IPSCIO Record ID: 1296

License Grant
The Company licensed rights to the use of MTCH-24(tm) against three viruses, the aids virus (hiv), Epstein-Barr virus and cytomegalovirus to a party for an ownership share.
License Property
MTCH-24 is an anti-microbial agent effective against a wide range of other enveloped viruses such as influenza, Epstein-Barr virus (EBV), respiratory syncytial virus (RSV, a virus which affects the respiratory system), pseudorabies (a specific virus in the rabies family), rhino tracheitis (an infection of the lungs and throat), and cytomegalovirus (CMV).  It is also believed to be effective against rotavirus, a non-enveloped virus that is a major cause of diarrhea and inflammation of the intestinal tract in infants and in certain animals.  MTCH-24 (TM) has been shown to be effective in inhibiting and preventing the growth of Aspergillus on wheat and corn.

IPSCIO Record ID: 3900

License Grant
Pursuant to an exclusive license agreement, the Company was granted exclusive Licenses in perpetuity for technologies developed by Licensor for the virus types HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies.

The Company and Licensor have agreed, in principle, to an amendment to the existing Licensing Agreement to include additional virus types among the virus types the Company is permitted to manufacture, use, and offer for sale, and, Licensor has permitted the Company to use its nanomaterials to develop treatments for Dengue viruses, Ebola/Marburg viruses, and viruses causing viral Conjunctivitis (a disease of the eye), until such time as the Company and Licensor can complete an amendment to the Licensing Agreement to include these additional virus types we are permitted to manufacture, use and offer for sale.

Field of Use
The rights granted apply to the healthcare industry relating to life-threatening viral infections.

IPSCIO Record ID: 390

License Grant
The Licensee of Vancouver, Canada, was granted the exclusive license for MTCH-24 and Viraplex® products worldwide outside of the United States.   We have developed two patented compounds MTCH-24(TM) and Viraplex(R). Both of these compounds show positive test results for treatment of a variety of enveloped viruses.
License Property
MTCH-24(TM) – Herpes I and II are enveloped viruses.  How MTCH-24 acts against enveloped viruses is not fully understood.  However, based on laboratory tests conducted for our company, MTCH-24 is believed to be effective against a wide range of other enveloped viruses such as influenza, Epstein-Barr virus (EBV), respiratory syncytial virus (RSV, a virus which affects the respiratory system), pseudo rabies (a specific virus in the rabies family), rhino tracheitis (an infection of the lungs and throat), and cytomegalovirus (CMV).   It is also believed to be effective against rotavirus, a non-enveloped virus that is a major cause of diarrhea and inflammation of the intestinal tract in infants and in certain animals.

Viraplex(R), which is intended to be administered orally in capsule form as a prescription treatment for oro-facial and genital Herpes simplex virus infections, is in an advanced phase (the third of three phases) of clinical testing for safety and effectiveness in humans although such clinical testing has been suspended pending refinancing of the Company.
Viraplex(R) gave positive in vitro results against several forms of cancer, including breast, prostate and lung tumors.

The Company has developed over-the-counter products containing MTCH-24(tm) for treating the symptoms of herpes simplex virus infections of the lips, mouth or face known as cold sores and for the treatment of acne collectively, the 'OTC products'.

IPSCIO Record ID: 243430

License Grant
This amendment addresses the sublicense consideration.

The original agreement is for the use of Herpes Simplex Virus Type 2 Antigens as Immunoprophylaxis or Immunotherapy to prevent or treat HSV Infections in Humans.

The University grants a Co-Exclusive license and a Tri-Exclusive license under the Licensed Patents to manufacture, have manufactured on Companys behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Field of Use in the Territory.

Tri-Exclusive means, with respect to a license, that such license may only be granted to Company and two Third Parties.

License Property
The research relates to the use of Herpes Simplex Virus Type 2 (HSV2) antigens as immunoprophylaxis or immunotherapy to prevent or treat HSV infections in humans.
Field of Use
The Field of Use means therapy that is administered to prevent or treat HSV2 infection.

IPSCIO Record ID: 257492

License Grant
Pursuant to the Agreement, Licensee obtained an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed Products in the Territory.

With this amendment the parties wish to amend the Agreement to provide for the reversion of rights to Licensor under the Licensor patent rights and know-how for Influenza vaccine, HPV vaccine and HSV vaccine.

As of the Amendment Effective Date, the license granted to Licensee, and the rights and obligations of Licensee and Licensor arising therefrom, shall no longer apply to Influenza vaccine, HPV Vaccine and HSV Vaccine, and these vaccines shall no longer be deemed to be Licensed Products under the Agreement.

Hereby amended Licensor grants to Licensee an exclusive license, even as to Licensor, under Licensor know-how and patent rights to develop, make, have made, use and sell Licensed products in the Territory with the right to grant sub licenses to Affiliates of Licensee and those persons or entities through whom Licensee, in the normal course of its business collaborates in the manufacture and sale of its products; provided however, that nothing in this Agreement shall prohibit Licensor from utilizing the Licensor know-how and/or patent rights, exclusive of Licensee know-how, to develop, make, have made, use and sell, either by itself or with one or more third parties, products for the treatment of infectious diseases provided, further, notwithstanding the preceding proviso, that Licensor shall not have any right to develop, make, have made, use, or sell, either by itself or with one or more third parties, Treatment Vaccines.

Licensor grants an option to obtain a license under theLicensor patent rights and know-how to make, have made, use, sell, offer to sell and import Cancer Vaccines in the Territory for up to three (3) Cancer targets. Such Cancer target license shall be exclusive, even as to Licensor, for each Cancer Target so licensed, and shall be sublicenseable by Licensee pursuant to the terms applicable to Licensed Products.

License Property
This amendment includes Amended Definitions Relating to Cancer targets, and, Licensed Product means a bulk or finished AIDS Vaccine, or other vaccine for the prevention of human infectious disease if licensed hereunder, which utilizes the Technology or technology which is developed by Licensor during and as a result of the research collaboration program; and upon the exercise of an Option for a Cancer vaccine, such bulk or finished Cancer vaccine for the prevention of Cancer Indications, provided, however, that if any vaccine is also capable of being used for treatment of the same human infectious disease or Cancer indication, then such therapeutic use of such vaccine shall also be considered a Licensed Product for purposes of the license being granted by Licensor to Licensee under this Agreement; and Treatment vaccines.

Treatment vaccines means a bulk or finished vaccine.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-1 in humans;  Hepatitis Virus (HBV) and or diseases caused by infection with HBV in humans; and Cancer vaccines for the treatment, but not prevention or prevention and treatment, of Cancer Indications.

IPSCIO Record ID: 299287

License Grant
Licensor grants to the Licensee of Korea an exclusive right and license in the Field under the Licensor Patent Rights, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale  Licensor Licensed Products in the Territory only.
License Property
Licensor has a universal influenza vaccine delivered with electroporation, SynCon â„¢ Universal influenza DNA vaccine in conjunction with electroporation.

The patents include Improved vaccines and methods for using the same;  Novel vaccines against multiple subtypes of influenza virus;  Influenza Nucleic acid molecules and vaccines made therefrom; and, Nucleic acid molecule encoding concensus influenza a hemagglutinin H!

SynCon™ technology enables the design of “universal” DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens such as influenza.

Field of Use
Field means a limitation on the application or utilization of Patent Rights to the field of DNA based vaccines against influenza that are delivered to a subject using electroporation, and its use to treat or protect a subject by delivering to such subject along with electroporation.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.